Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
71 hedge funds and large institutions have $86.1M invested in Endocyte, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 17 closing their positions.
626% more capital invested
Capital invested by funds: $11.9M → $86.1M (+$74.2M)
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
13% more funds holding
Funds holding: 63 → 71 (+8)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
59% less call options, than puts
Call options by funds: $737K | Put options by funds: $1.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$16.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16M |
| 3 |
D.E. Shaw & Co
New York
|
+$7.91M |
| 4 |
PA
Perceptive Advisors
New York
|
+$6.92M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.63M |
| 2 |
Millennium Management
New York
|
-$609K |
| 3 |
SIM
Spark Investment Management
New York
|
-$569K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$383K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$353K |
ECYT Hedge Fund Activity: Q4 2017 in Review
71 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2017, worth a combined $86.1M — up 626% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ECYT positions and 17 closed out — a net gain of 8 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $16.4M. The largest seller was Fidelity Investments, cutting an estimated $1.63M.
- 71 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2017, up from 63 in Q3 2017.
- Funds reported $86.1M of Endocyte, Inc. Common Stock stock for Q4 2017, up 626% quarter-over-quarter.
- 25 funds opened new Endocyte, Inc. Common Stock positions in Q4 2017 and 17 closed out, a net change of +8 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q4 2017 was PFM Health Sciences, an estimated $16.4M added.
- The largest Endocyte, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2017.